Effects of beraprost sodium on plasma VEGF and ET-1 in elderly patients with type 2 diabetic nephropathy / 中华内分泌外科杂志
Chinese Journal of Endocrine Surgery
; (6): 463-465, 2013.
Article
in Zh
| WPRIM
| ID: wpr-622010
Responsible library:
WPRO
ABSTRACT
Objective To observe the effect of beraprost sodium on elderly patients with type 2 diabetic nephropathy (DN) and to observe the change of the plasma vascular endothelial growth factor(VEGF) and endothelin(ET-1) level.Methods The levels of plasma VEGF and ET-1 in the 27 cases of type 2 diabetes without nephropathy and 48 cases with type 2 diabetic nephropathy were measured.The possible role of VEGF and ET-1 in diabetic nephropathy was explored.48 cases of type 2 diabetic nephropathy patients were randomly divided into 2 groups:the conventional treatment group and beraprost sodium treatment group.The changes of VEGF and ET-1 level in the 2 groups before and after the treatment were measured.Results The plasma VEGF and ET-1 levels were significantly higher in type 2 diabetic nephropathy patients than in type 2 diabetes patients without nephropathy(P <0.01).Compared with the control group,beraprost sodium significantly reduced the plasma VEGF and ET-1 levels in patients with diabetic nephropathy(P < 0.05),and also reduced urinary albumin excretion rates (UAER) significantly (P < 0.05).Conclusions The increasing level of VEGF and ET-1 plays an important role in the onset of diabetic nephropathy.Beraprost sodium can correct the balance of the plasma VEGF and ET-1 in treatment of patients with diabetic nephropathy,improves the endothelial function in diabetic nephropathy,decreases urine protein,and plays a protective role in diabetic nephropathy.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Endocrine Surgery
Year:
2013
Type:
Article